RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 2

Registered title, quoted from ClinicalTrials.gov

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07652905, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use effective contraception from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.

    Inclusion criterion 24

  3. Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;

    Inclusion criterion 11

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.

    Inclusion criterion 12

    White blood cell (WBC) count ≥1.5 × 10⁹/L;

    Inclusion criterion 15

    Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L;

    Inclusion criterion 16

    Hemoglobin ≥70 g/L;

    Inclusion criterion 17

    Platelet count ≥50 × 10⁹/L;

    Inclusion criterion 18

    At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;

    Inclusion criterion 21

    At least 1 week between the last platelet transfusion and platelet count assessment at screening.

    Inclusion criterion 22

  4. Pregnant or breastfeeding women.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07652905, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able to understand and voluntarily sign a written informed consent form (ICF).
  • Age 18 to 75 years.
  • Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as either:
  • ≥5% circulating plasma cells on peripheral blood smear; or
  • Absolute circulating plasma cell count >2 × 10⁹/L.

Patients who have received no more than one prior cycle of anti-myeloma therapy before enrollment are eligible.

  • Measurable disease, defined by at least one of the following:
  • Serum M-protein ≥10 g/L as measured by serum protein electrophoresis (SPEP); for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead;
  • Urine M-protein ≥200 mg/24 hours;
  • If neither serum nor urine M-protein meets the above criteria, involved serum free light chain (FLC) ≥100 mg/L with an abnormal serum FLC ratio (normal range: 0.26-1.65).
  • Adequate hepatic function, defined as:
  • Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.
  • Adequate renal function, defined as creatinine clearance ≥30 mL/min, calculated using the Cockcroft-Gault formula.
  • Adequate hematologic function within 7 days prior to enrollment, defined as:
  • White blood cell (WBC) count ≥1.5 × 10⁹/L;
  • Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L;
  • Hemoglobin ≥70 g/L;
  • Platelet count ≥50 × 10⁹/L;

Alternatively, eligibility may be determined by the investigator based on clinical judgment.

  • Participants receiving hematopoietic growth factor support, including erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or thrombopoietic agents, must have a washout period of at least 2 weeks between the last administration of growth factor support and screening assessments.
  • Participants receiving blood product transfusions must meet the following requirements:
  • At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;
  • At least 1 week between the last platelet transfusion and platelet count assessment at screening.
  • Able and willing to receive protocol-recommended prophylactic anticoagulation therapy.
  • Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use effective contraception from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.

Male participants, including those who have undergone vasectomy, must agree to use condoms during sexual intercourse with women of childbearing potential and must not plan to father a child from the time of signing informed consent through 3 months after the last dose of study treatment.

Exclusion Criteria:

  • Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or secondary plasma cell leukemia.
  • Central nervous system (CNS) involvement or clinical evidence of leptomeningeal involvement.
  • Known intolerance, hypersensitivity, allergy, or contraindication to CM336, isatuximab, bortezomib or lenalidomide.
  • Severe and/or uncontrolled cardiovascular disease, including:

Unstable angina; Symptomatic congestive heart failure; Myocardial infarction within 6 months prior to enrollment; Severe and uncontrolled cardiac arrhythmias; Any other cardiovascular or cerebrovascular condition deemed by the investigator to make participation inappropriate.

  • Active infection, including:

Human immunodeficiency virus (HIV) infection; Active hepatitis B infection (HBV DNA positive); Active hepatitis C infection (HCV RNA positive); Active or latent syphilis infection (positive Treponema pallidum antibody test); Active pulmonary tuberculosis, as evidenced by chest imaging or other relevant assessments within 3 months prior to screening or during the screening period; Any other infection considered by the investigator to make participation inappropriate.

  • Concurrent active malignancy or any serious concomitant disease that, in the investigator's judgment, could compromise participant safety or interfere with study participation.
  • Pregnant or breastfeeding women.
  • Estimated life expectancy of less than 6 months.
  • Active gastrointestinal disorders that may impair the participant's ability to swallow oral medication or may interfere with the absorption of study treatment.
  • Major surgery within 2 weeks prior to enrollment (e.g., surgery requiring general anesthesia), incomplete recovery from prior surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Participants undergoing procedures under local anesthesia may be eligible.
  • Receipt of a live attenuated vaccine within 4 weeks before the first dose of study treatment.
  • Any active severe psychiatric disorder, medical condition, symptom, or other circumstance that, in the investigator's judgment, may interfere with treatment, protocol compliance, or the ability to provide informed consent.
  • Inability or unwillingness to provide written informed consent.

Quoted from ClinicalTrials.gov, NCT07652905, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07652905, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07652905